Trade

with

Oramed Pharmaceuticals Inc
(NASDAQ: ORMP)
AdChoices
7.62
-0.33
-4.15%
After Hours :
-
-
-

Open

8.35

Previous Close

7.95

Volume (Avg)

61.70k (51.53k)

Day's Range

7.60-8.35

52Wk Range

6.19-31.73

Market Cap.

75.86M

Dividend Rate ( Yield )

-

Beta

0.23

Shares Outstanding

9.96M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -4.23M

    • Market Cap.

    • 75.86M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.23

    • Forward P/E

    • -

    • Price/Sales

    • -

    • Price/Book Value

    • 3.60

    • Price/Cash flow

    • -19.34

      • EBITDA

      • -4.12M

      • Return on Capital %

      • -35.53

      • Return on Equity %

      • -37.18

      • Return on Assets %

      • -35.53

      • Book Value/Share

      • 2.21

      • Shares Outstanding

      • 9.96M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 32.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 32.26

              • 2.92

              • Quick Ratio

              • 31.94

              • 2.35

              • Interest Coverage

              • 333.32

              • 38.02

              • Leverage Ratio

              • 1.02

              • 2.21

              • Book Value/Share

              • 2.21

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -14.12

                • 277.78

                • P/E Ratio 5-Year High

                • -56.40

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.27

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.35

                • Price/Book Value

                • 3.60

                • 8.50

                • Price/Cash Flow Ratio

                • -19.34

                • 50.25

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -37.18

                        (-94.10)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -35.53

                        (-74.70)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -37.30

                        (-96.60)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • -

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -4.30M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -19.34
                      Ownership

                      Institutional Ownership

                      28.18%

                      Top 10 Institutions

                      31.40%

                      Mutual Fund Ownership

                      3.46%

                      Float

                      77.71%

                      5% / Insider Ownership

                      -

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • MassMutual Select Small Cap Growth Eq

                      •  

                        110,355

                      • 55.40

                      • 1.11

                      • SEI Small/Mid Cap Equity (SIIT)

                      •  

                        84,826

                      • 0.00

                      • 0.84

                      • SEI Small Cap (SIIT)

                      •  

                        41,854

                      • 0.00

                      • 0.42

                      • MassMutual Select Small Company Growth

                      •  

                        31,614

                      • 62.83

                      • 0.32

                      • SEI Small Cap (SIMT)

                      •  

                        31,238

                      • 0.00

                      • 0.31

                      • SEI Small Cap II (SIIT)

                      •  

                        23,690

                      • 0.00

                      • 0.24

                      • Montibus Small Cap Growth Fund

                      •  

                        17,782

                      • 88.07

                      • 0.18

                      • SEI Small Cap Growth (SIMT)

                      •  

                        16,059

                      • 0.00

                      • 0.16

                      • Fidelity® NASDAQ Composite Index® Fund

                      •  

                        1,051

                      • 0.00

                      • 0.01

                      • FlexShares Mstar US Mkt Factors Tilt ETF

                      •  

                        1,032

                      • 0.00

                      • 0.01

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Regals Management LP

                      •  

                        1,376,385

                      • +80.95%

                      • 17.32

                      • Awm Investment Company Inc

                      •  

                        790,000

                      • 0.00%

                      • 7.94

                      • Montibus Capital Management LLC

                      •  

                        413,664

                      • +64.70%

                      • 4.15

                      • Greylin Investment Mangement Inc

                      •  

                        91,200

                      • +7.42%

                      • 0.92

                      • Susquehanna Financial Group, LLLP

                      •  

                        28,579

                      • +17.70%

                      • 0.29

                      • Tocqueville Asset Management L.P.

                      •  

                        15,000

                      • 0.00%

                      • 0.15

                      • HSBC Holdings PLC

                      •  

                        15,000

                      • 0.00%

                      • 0.15

                      • Morgan Stanley & Co Inc

                      •  

                        8,863

                      • +1.54%

                      • 0.09

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Oramed Pharmaceuticals Inc. was incorporated on April 12, 2002, under the laws of the State of Nevada. It is a pharmaceutical Company engaged in the research and development of innovative pharmaceutical solutions, including an orally...more ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. The Company is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD0801) currently in Phase 2 clinical trials. The Company plans to continue to conduct clinical trials to show the effectiveness of its technology. It filed two...more additional provisional patents for a suppository application to its technology portfolio. The first patent focuses on a rectal application for insulin. The second patent focuses on the usage of this rectal application to other polypeptides that at present are only available in injection. On September 16, 2008 it announced the launch of pre-clinical trials of ORMD 0901, a GLP1-analog. The Company has agreements with Vetgenerics Research G. Ziv Ltd., a clinical research organization, to conduct a toxicology trial on its oral insulin capsules. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.lessless

                      Key People

                      Mr. Nadav Kidron

                      CEO/President/Director

                      Yifat Zommer

                      CFO/Chief Accounting Officer/Secretary/Treasurer

                      Leonard Sank

                      Director

                      Dr. Miriam Kidron,PhD

                      Director/Chief Medical Officer/Chief Technology Officer

                      Harold Jacob

                      Director

                      • Oramed Pharmaceuticals Inc

                      • Hi-Tech Park 2/4

                      • Jerusalem, 91390

                      • USA.Map

                      • Phone: +972 25660001

                      • Fax: +972 25660004

                      • oramed.com

                      Incorporated

                      2002

                      Employees

                      10

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: